Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Immunic, Inc. (IMUX : NSDQ)

• Company Description    Immunic Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis and psoriasis. The company's product candidate consists of IMU-838, IMU-935 and IMU-856 which are in clinical stage. Immunic Inc., formerly known as Vital Therapies Inc., is based in San Diego, United States. Number of Employees: 91

• Price / Volume Information    Yesterday's Closing Price: $0.84 Daily Weekly Monthly 20 Day Moving Average: 1,575,262 shares Shares Outstanding: 95.82 (millions) Market Capitalization: $80.28 (millions) Beta: 1.49 52 Week High: $2.11 52 Week Low: $0.56 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -0.72% -4.44% 12 Week -14.51% -28.09% Year To Date -16.22% -21.54%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1200 AVENUE SUITE 200 - NEW YORK,NY 10036 USA ph: 332-255-9818 fax: 858-673-6843 investorrelations@vitaltherapies.com http://www.immunic-therapeutics.com

• General Corporate Information    Officers Daniel Vitt - Director; Chief Executive Officer Duane D. Nash - Executive Chairman Glenn Whaley - Chief Financial Officer Tamar Howson - Director Joerg Neermann - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 4525EP101 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/14/25 Share - Related Items Shares Outstanding: 95.82 Most Recent Split Date: 4.00 (0.03:1) Beta: 1.49 Market Capitalization: $80.28 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.18 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.76 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 0.00% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -326.95 12/31/24 - -185.13 ROA 06/30/25 - - 03/31/25 - -181.34 12/31/24 - -129.22 Current Ratio 06/30/25 - - 03/31/25 - 0.74 12/31/24 - 1.77 Quick Ratio 06/30/25 - - 03/31/25 - 0.74 12/31/24 - 1.77 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - -0.06 12/31/24 - 0.20 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - 0.00

Powered by Zacks Investment Research ©